Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Caraco Pharmaceutical Laboratories Inc. (CPD) Gets Back on Track in Generic Drug Market

Companies often stumble in certain areas only to come back stronger and more profitable as issues are addressed and overcome. In certain areas, this particular type of problem is more easily overcome then in others, especially when the profit potential is exceedingly large. The generic drug market is one such area and one that will be extremely profitable in coming years.

Caraco Pharmaceutical Laboratories Inc., a generic drug manufacturer, works to provide generic drugs to a host of mass merchant pharmacy outlets, warehouses, wholesalers and distributors. The company offers a wide array of generic prescription drugs targeted at main stream diseases.

Although the pharma sector has been finding solid successes of late and banked solid capital reserves, there is certain trepidation with regard to product going “off-patent” in the relative near-term. There are many new products to fill this “off-patent” issue, but many products that will leave the patent scenario have been highly profitable. In this regard, companies other than the patent owning companies will be able to benefit.

Caraco Pharmaceutical is one such company. It is also one that is very well diversified in terms of the generic drugs it offers. Conditions that the company offers product to include but are not limited to: analgesics, antibiotics, anticonvulsants, antidepressants, antidiabetics, anti-gouts, antihypertensive/beta blockers, antipsychotics, anti ulcerants, cardiac, decongestants, and narcotic analgesics. The company’s therapeutic drugs also include nonsteroidal antiinflammatory agents, opiate agonist/analgesics, oncology adjuncts, Parkinson’s disease, platelet aggregation inhibitors, sedatives and hypnotics, skeletal muscle relaxants and migraine headache suppressants.

As of 11:30 AM EST, the company is trading up 22.33%. Moving forward the company does appear to be offering product in many high value areas. Looking over past issues, it would appear that Caraco Pharmaceuticals is well positioned to take advantage of off-patent opportunities and will likely find solid profit opportunity in many high value areas.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *